Antidepressant activity of fingolimod in mice

Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Both mechanisms are relevant to the path...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmacol Res Perspect
Asıl Yazarlar: di Nuzzo, Luigi, Orlando, Rosamaria, Tognoli, Cristina, Di Pietro, Paola, Bertini, Giuseppe, Miele, Jessica, Bucci, Domenico, Motolese, Marta, Scaccianoce, Sergio, Caruso, Alessandra, Mauro, Gianluca, De Lucia, Carmine, Battaglia, Giuseppe, Bruno, Valeria, Fabene, Paolo Francesco, Nicoletti, Ferdinando
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492751/
https://ncbi.nlm.nih.gov/pubmed/26171219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.135
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller